COMMUNIQUÉS West-GlobeNewswire

BridgeBio to Present Long-Term Efficacy and Safety Data from the ATTRibute-CM OLE Trial at the ACC Annual Scientific Sessions
23/03/2026
PALO ALTO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, announced [...]
Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy
23/03/2026
MALVERN, Pa., March 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a [...]
Sapu Nano to Present Everolimus Toxicology Data at SOT 2026 Annual Meeting
23/03/2026
AGOURA HILLS, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), a leader in RNA-based therapeutics, announced today that its subsidiary [...]
Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
23/03/2026
OPUS-1 Phase 3 Study Designed to Establish a New Standard for Adult Pneumococcal Conjugate Vaccines (PCVs) Through Head-to-Head Safety, Tolerability and Immunogenicity Comparisons of VAX-31 with Capvaxive ® (PCV21) and [...]
Kraig Biocraft Laboratories Increases R&D Capacity, as Project Atlas Breakthroughs Creating New Spider Silk Transgenics
23/03/2026
ANN ARBOR, Mich., March 23, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company", "Kraig Labs", or "Kraig's"), a world leader in spider silk technology*, today announced a significant [...]
Novo Nordisk A/S - share repurchase programme
23/03/2026
Bagsværd, Denmark, 23 March 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 ( [...]
NKGen Biotech Reports Combined Phase 1 Troculeucel Data Demonstrating Dose-Responsive Cognitive Improvements and Biomarker Correlations in Alzheimer’s Disease at AD/PD 2026™
23/03/2026
Pooled analyses in patients with moderate Alzheimer’s show dose-related cognitive benefit and signs of durability. 100% of patients remained stable or improved, with 50% improving from moderate to mild cognitive [...]
MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer
23/03/2026
ROCKVILLE, Md., March 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and [...]
Reviva Pharmaceuticals Holdings, Inc. Announces Closing of $10 Million Public Offering
23/03/2026
CUPERTINO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet [...]
MIMEDX Announces Launch of CHORIOFIX™
23/03/2026
Further Expands Company’s Broad Portfolio of Advanced Wound Care (“AWC”) Products MARIETTA, Ga., March 23, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the [...]
Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
23/03/2026
Strong financial position with cash, cash equivalents and marketable securities of $91.5M as of December 2025 $2.25B Moderna global settlement for infringement of lipid nanoparticle (LNP) delivery technology represents [...]
Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851
23/03/2026
LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associated metabolic disorders Lexicon has earned a second of three potential $10 million near- [...]
Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services
23/03/2026
Ms. McDonough previously served as Senior Vice President of Patient Access, Analytics, and Operations at Krystal Biotech (Nasdaq: KRYS), where she helped lead the U.S. launch of VYJUVEK®, supporting its growth from FDA [...]
TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus
23/03/2026
IRVINE, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced that a $15 million milestone payment due Tarsus has been achieved following regulatory approval of TP-03 ( [...]
Theriva™ Biologics Announces Positive End-of-Phase 2 Meeting with U.S. FDA Regarding the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma
23/03/2026
– Successful meeting with FDA enables advancement into proposed Phase 3 clinical trial of VCN-01 in combination with gemcitabine/nab-paclitaxel for the first-line treatment of metastatic PDAC – – Combined feedback from [...]
NÖK Therapeutics to Present Long-Term Clinical Data at the 11th Annual Innate Killer Summit
23/03/2026
CRANBERRY TOWNSHIP, Pa., March 23, 2026 (GLOBE NEWSWIRE) -- NÖK Therapeutics, Inc. (“NÖK” or the “Company”), a clinical-stage biotechnology company advancing autologous Natural Killer (“NK”) cell immunotherapies, today [...]
NovaBay Pharmaceuticals Announces Name Change to Stablecoin Development Corporation, Reports Initial Staking Rewards, and Provides SKY Token Holdings Update
23/03/2026
Following $134 million investment from R01 Fund LP, Framework Ventures, Tether Investments, S.A. de C.V., and Sky Frontier Foundation, Stablecoin Development Corporation has acquired 2.06 billion SKY tokens Key [...]
NewAmsterdam Pharma Announces Three Presentations at the 2026 American College of Cardiology Annual Scientific Session
23/03/2026
NAARDEN, The Netherlands and MIAMI, March 23, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral [...]
Leading Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan of Arrangement
23/03/2026
Shareholders are Recommended to Vote “FOR” the Aptose Biosciences Proposed Plan of Arrangement with Hanmi Pharmaceutical Shareholders are Reminded of Voting Deadline for Upcoming Special Meeting SAN DIEGO and TORONTO, [...]

Pages